# Re-evaluation Task: LUN-003

## Context
- **Case ID**: LUN-003
- **Cancer type**: Small cell lung cancer — extensive stage (ES-SCLC)
- **Stage**: Stage III (extensive stage)
- **Molecular profile**: RB1 loss, TP53 mutated
- **Report file**: experiment_reports\LUN-003_report.json
- **Current score**: 86/100
- **Gap analysis (local GPU)**: The most critical gaps in LUN-003's research report are the lack of data on Atezolizumab + Carboplatin + Etoposide (IMpower133) and Lurbinectedin + Atezolizumab Maintenance (IMforte), as these combinations have shown promise in clinical trials but require more comprehensive evaluation to improve the score. Filling these gaps with high-quality data will enable a more thorough assessment of these regimens, providing valuable insights into their efficacy and safety profiles that can inform treatment decisions for patients with cancer.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  14/25  |  56.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| source_quality                      |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (56.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\LUN-003_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Small cell lung cancer — extensive stage (ES-SCLC)",
    "stage": "Stage III (extensive stage)",
    "molecular_profile": [
      "RB1 loss",
      "TP53 mutated"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Atezolizumab + Carboplatin + Etoposide (IMpower133 regimen)",
      "category": "Standard of Care",
      "composite_rating": 8.5,
      "rating_breakdown": {
        "evidence_level": {
          "score": 10,
          "rationale": "Phase 3 RCT IMpower133 with 403 patients randomized. Category 1 NCCN recommendation. Replicated in real-world studies. 5-year follow-up data available from IMbrella A extension."
        },
        "survival_benefit": {
          "score": 7,
          "rationale": "Median OS 12.3 vs 10.3 months (HR 0.70, p=0.007). PFS 5.2 vs 4.3 months. 5-year OS rate of 12% vs historical 2% with chemo alone — a 6-fold improvement in long-term survivors. Modest absolute gain but meaningful relative improvement."
        },
        "accessibility": {
          "score": 10,
          "rationale": "FDA approved since March 2019 as first-line for ES-SCLC. Universally available at oncology centers worldwide. NCCN Category 1 preferred regimen."
        },
        "safety_profile": {
          "score": 6,
          "rationale": "Standard platinum-doublet toxicity profile: myelosuppression (grade 3-4 neutropenia ~22%), nausea, fatigue, alopecia. Immune-related AEs include rash, hepatitis, hypothyroidism. Manageable with standard supportive care. Diabetes comorbidity requires monitoring for immune-mediated endocrinopathies."
        },
        "biomarker_match": {
          "score": 10,
          "rationale": "No biomarker selection required — benefits all ES-SCLC patients regardless of PD-L1 status. TP53/RB1 mutations are near-universal in SCLC and do not affect eligibility or response."
        }
      },
      "mechanism_of_action": "Atezolizumab (anti-PD-L1) blocks PD-L1/PD-1 interaction restoring anti-tumor T-cell immunity. Combined with carboplatin (DNA cross-linking) and etoposide (topoisomerase II inhibition) for cytotoxic cell kill. Immunogenic cell death from chemotherapy may enhance checkpoint inhibitor efficacy.",
      "key_evidence": {
        "study_name": "IMpower133",
        "journal": "New England Journal of Medicine / Journal of Clinical Oncology",
        "year": 2018,
        "sample_size": 403,
        "os_months": {
          "treatment": 12.3,
          "control": 10.3,
          "hazard_ratio": 0.7,
          "p_value": 0.007
        },
        "pfs_months": {
          "treatment": 5.2,
          "control": 4.3
        },
        "orr_percent": {
          "treatment": 60,
          "control": 64
        }
      },
      "biomarker_requirements": [],
      "notable_side_effects": [
        "grade 3-4 neutropenia (~22%)",
        "anemia",
        "thrombocytopenia",
        "immune-related hepatitis",
        "
... (truncated — read full file from experiment_reports\LUN-003_report.json)
```
